PacBio Announces Novogene's Use Of Revio Long-Read Sequencing System In New Munich Lab To Serve European Scientific Community; Enhanced Accuracy And Throughput To Support Genomic Research In Rare Diseases, Cancer, Microbes, And Agriculture
Portfolio Pulse from Benzinga Newsdesk
PacBio announced that Novogene will use its Revio long-read sequencing system in a new Munich lab to serve the European scientific community. This system will enhance accuracy and throughput, supporting genomic research in rare diseases, cancer, microbes, and agriculture.
July 23, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PacBio's Revio long-read sequencing system will be utilized by Novogene in a new Munich lab, enhancing genomic research capabilities in Europe.
The partnership with Novogene and the deployment of the Revio system in a new lab in Munich is likely to enhance PacBio's market presence and credibility in the European scientific community. This could lead to increased demand for their products and services, positively impacting their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100